4.8 Article

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator

期刊

CELL REPORTS
卷 25, 期 10, 页码 2808-+

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2018.11.035

关键词

-

资金

  1. National Cancer Institute [R01CA172384, P50CA180995, R50CA211271]
  2. American Cancer Society Research Scholar Award [RSG-12-085-01]
  3. Department of Defense [PC160328]
  4. National Institute of Diabetes and Digestive and Kidney Diseases [T32 DK007169]
  5. NATIONAL CANCER INSTITUTE [R50CA211271, R01CA227918, P50CA180995, R01CA172384] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Enhancer of Zeste 2 (EZH2) is the enzymatic subunit of Polycomb RepressiveComplex 2 (PRC2), which catalyzes histone H3 lysine 27 trimethylation (H3K27me3) at target promoters for gene silencing. Here, we report that EZH2 activates androgen receptor (AR) gene transcription through direct occupancy at its promoter. Importantly, this activating role of EZH2 is independent of PRC2 and its methyltransferase activities. Genome-wide assays revealed extensive EZH2 occupancy at promoters marked by either H3K27ac or H3K27me3, leading to gene activation or repression, respectively. Last, we demonstrate enhanced efficacy of enzymatic EZH2 inhibitors when used in combination with AR antagonists in blocking the dual roles of EZH2 and suppressing prostate cancer progression in vitro and in vivo. Taken together, our study reports EZH2 as a transcriptional activator, a key target of which is AR, and suggests a drug-combinatory approach to treat advanced prostate cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据